Dear Editor, The demands of social distancing during the novel coronavirus (COVID-19) pandemic have upended standard healthcare workflows through travel limitations, site closures, and interruptions of medication supply chains (U.S. Food and Drug Administration, 2020). These changes have impacted the conduct of highly-choreographed clinical trials, which require timely visits and assessments in order to maintain scientific validity in evaluating the safety and efficacy of novel medications ([@bib2]; U.S. Food and Drug Administration, 2020).

In response to the logistic and economic uncertainties of the current times, some clinical trials have been suspended or will not begin as originally planned due to the global pandemic ([@bib3]). We sought to investigate the impact of the COVID-19 outbreak on dermatology-related clinical trials by examining publicly available clinical trials data.

Methods {#sec1}
=======

We queried [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0025}, a global repository of privately and publicly funded clinical studies, to identify clinical trials related to dermatologic conditions using the search terms 'dermatologic diseases,' 'skin diseases,' and 'skin disorders' from April 1, 2019 through May 31, 2020. For interventional trials listed as withdrawn, suspended, or terminated, the date the trial listing was last updated was used as a proxy for when the trial's status was changed. We excluded trials that were not related to dermatology, listed as completed, had not posted updates, or had not been verified by [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0030} within the past two years. We also excluded trials that had been withdrawn, terminated, or suspended before March 1, 2019.

Information on the trial's name, related condition(s), estimated enrollment, last update, and current status (suspended, withdrawn, terminated, active not recruiting, recruiting, and enrolling by invitation) were collected. "Active, not recruiting" trials include ongoing studies with participants that are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled. For any trials suspended in March, April or May 2020, we reviewed any listed reasons for trial closures and documented if this reason was specifically attributed to COVID-19.

Although we were unable to ascertain the total number ongoing dermatology trials in 2019, we performed a sensitivity analysis using chi-squared analysis to determine the minimum number of ongoing trials required in 2019 to ensure that the change in the proportion of trial suspensions, terminations and withdrawals in March -- May 2019 was different than the proportion of trial suspensions, terminations and withdrawals in March -- May 2020 (defined as p \< 0.05).

Results {#sec2}
=======

We identified 1010 active (not recruiting), recruiting, and enrolling by invitation trials for dermatologic conditions, with estimated enrollment of 284,881 patients. 293 (29%) of trials were listed as active (not recruiting) with enrollment of 121,310 patients. 92 trials had been suspended, withdrawn, or terminated (92/1010, 9.1% of ongoing dermatology-related clinical trials). Over half of the suspensions, terminations, and withdrawals occurred in March, April and May of 2020 (N=57/92, 62%; [Figure 1](#fig1){ref-type="fig"} ), with estimated enrollment of 7,141 patients (7141/292022, 2.4% of all patients enrolled in dermatology trials). There were 17, 21 and 7 excess dermatology trial suspensions, terminations and withdrawals that occurred in March, April and May of 2020 respectively in comparison to March, April and May of 2019 ([Table 1](#tbl1){ref-type="table"} ).Fig 1Trials for dermatologic conditions that were suspended, withdrawn, or terminated between April 1, 2019 and May 31, 2020. **Suspended trials:** The study has stopped early but may start again. **Terminated trials:** The study has stopped early and will not start again. Participants are no longer being examined or treated. **Withdrawn trials:** The study stopped early, before enrolling its first participant.Table 1Excess trial suspensions, withdrawals, and terminations in March -- May 2019 relative to suspensions, withdrawals and terminations in March -- May 2020MarchAprilMayTotalSuspensions, Withdrawals and Terminations 2019\
Number of Trials \| Number of Patients2 \| 907 \| 03 \| 45012 \| 540Suspensions, Withdrawals and Terminations 2020\
Number of Trials \| Number of Patients19 \| 154528 \| 468010 \| 91657 \| 7839Excess Suspensions, Withdrawals and Terminations\
Number of Trials \| Number of Patients17 \| 145521 \| 46807 \| 46645 \| 6601

Among affected trials, 5,607 patients (79%) were enrolled in 32 trials (56%) listed as suspended specifically due to the COVID-19 pandemic. The most common COVID-19 trial suspensions were for atopic dermatitis (N=7), psoriasis (N=7), and hidradenitis suppurativa (N=5). Most (63%, 20/32) of COVID-19 affected trials were Phase 2 and 3 trials. 44% (14/32) of the COVID-19 affected trials had estimated enrollment greater than 100 patients.

Our sensitivity analysis revealed that the proportion of trial suspensions, withdrawals and terminations in March, April, and May of 2020 (N = 57) was significantly more than the proportion of trial suspensions, withdrawals and terminations occurring in March, April, and May 2019 (N = 12, *p* \< 0.05), assuming that the number of active, not recruiting, recruiting and enrolling trials (eg. ongoing trials) in 2019 did not fall below 398 (61% less than the number of ongoing trials in 2020).

Discussion {#sec3}
==========

We observed an increase in the suspension, withdrawal, and termination of clinical trials for dermatologic conditions during the initial months of the COVID-19 pandemic, many of which were attributed specifically to the coronavirus outbreak. These changes have substantial implications for currently enrolled patients, as clinical trials provide patients with skin disorder treatments that can significantly improve their clinical outcomes and quality of life ([@bib5]).

The reverberations of clinical trial closures will not only affect patients during the pandemic but will also extend well beyond this timeframe. Halting clinical trials, which serve as the basis for regulatory approval of novel treatments (U.S. Food and Drug Administration, 2020), can create considerable delays in drug development.

Barriers to the treatment and timely assessment of trial enrollees may also threaten the integrity of clinicals trials data and limit their interpretation ([@bib4]). Furthermore, the financial impact of trial closures and reassignment of study personnel may alter available infrastructure for future trials. Additional studies are necessary to investigate the impact of trial closures on both trial integrity and infrastructure.

The results of our study must be interpreted within the context of our study design. Our sensitivity analysis was simple and unadjusted. While ClinicalTrials.gov requires responsible parties to update their records within 30 days of a change to individual site and overall recruitment status (ClinicalTrials.gov, 2020), it is possible that some sponsors do not change the status of their studies in a timely manner ([@bib6]). Additionally, a multi-site trial's overall recruitment status may have remained unchanged if only a subset of its sites experienced closures. Our study may therefore underestimate the number of trials affected.

Although our data show a spike in trial suspensions, withdrawals, and terminations over the past 3 months, longitudinal data is required to determine the complete scope of the impact of COVID-19 on dermatology trials. Until then, development and dissemination of best practices to maintain patient safety and trial integrity are essential to maintaining the progress of therapeutic development within dermatology.

**Data Availability:** Datasets related to this article can be found at https://clinicaltrials.gov/, an online data repository hosted at ClinicalTrials.gov (Home - ClinicalTrials.gov. Clinicaltrials.gov. https://clinicaltrials.gov/. Published 2020. Accessed May 15, 2020.)
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